🇺🇸

US SEC Filing Intelligence

· daily

Contract Deobligations Alert — July 31, 2026

This digest covers $1.07 billion in federal contract obligations from July 31, 2026, with zero defense-related awards, underscoring a purely civilian procurement theme. The dominant sector is environmental remediation, led by a $371.6 million DOE Hanford award to Central Plateau Cleanup Company (PAE-Parsons), though its short duration and low outlay limit near-term impact. The highest-conviction signal is a $173.3 million NIH clinical research contract to Technical Resources International, offering a stable, long-term revenue stream through 2026. Key risks include the expiration of a $321.3 million Serco DHS contract with no current outlay and the completion of a $202.6 million NASA engineering award to Millennium Engineering, both reducing current revenue visibility for those firms.

4 total filings
· daily

Contract Option Exercises — July 31, 2026

This digest covers $1.07 billion in contract option exercises from July 31, 2026, all from civilian agencies (0% defense-related), with an average signal strength of 5.0/10. The dominant theme is federal environmental remediation and health R&D services, led by a $371.6 million DOE Hanford cleanup award to Central Plateau Cleanup Company (PAE-Parsons) and a $173.3 million NIH clinical research contract to Technical Resources International. The highest-conviction signal is the bullish, long-duration NIH contract to Technical Resources International, which provides stable, low-risk revenue through 2026. A key risk is the short 8-month performance period and low outlay ($125.4M) on the largest contract, limiting near-term revenue visibility for PAE-Parsons.

4 total filings
· daily

All HHS Contracts — July 31, 2026

The sole contract in this digest is a $173.3 million cost-plus-fixed-fee award from the National Institutes of Health (NIH) to Technical Resources International, Inc. for clinical research operations and management support (CROMS), spanning 2017-2026. This is a purely civilian award with no defense-related content, underscoring NIH's sustained investment in health R&D services. The highest-conviction signal is the low pricing risk and long-term revenue stability afforded by the cost-plus structure, providing predictable margins for a small business. Key watch items include potential contract modifications or extensions beyond July 2026 and the company's ability to scale operations given its small business status.

1 total filings
· daily

All DOE Contracts — July 31, 2026

This digest covers a single Department of Energy (DOE) contract totaling $371.6 million, with zero defense-related content, underscoring a purely civilian environmental remediation theme. The dominant signal is neutral: Central Plateau Cleanup Company, LLC (a PAE-Parsons joint venture) received a cost-plus award fee delivery order for Hanford site cleanup, but the short 8-month performance period and low outlay-to-obligation ratio ($125.4M out of $371.6M) limit near-term revenue visibility. The highest-conviction signal is the sustained DOE commitment to legacy nuclear waste remediation, though the cost-plus structure caps profit upside. A key risk is the contract’s expiration on September 30, 2021, with no guarantee of option exercise, creating a binary event for PAE-Parsons’ DOE revenue stream.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — July 31, 2026

This digest covers $1.07 billion in federal contract obligations, all from civilian agencies, with zero defense exposure. The dominant theme is long-duration, cost-plus environmental and health R&D services, led by a $371.6 million DOE Hanford cleanup award to Central Plateau Cleanup Company (PAE-Parsons) and a $173.3 million NIH clinical research contract to Technical Resources International. The highest-conviction signal is the bullish, decade-long NIH award to Technical Resources International, which offers stable, low-risk revenue for a small, woman-owned business. A key risk is the short 8-month performance period on the largest contract (DOE/Hanford), limiting near-term revenue visibility despite the high obligation amount.

4 total filings
· daily

High-Value Federal Grants ($5M+) — July 31, 2026

This digest covers $1.07 billion in aggregate obligations across four civilian agency contracts, with zero defense exposure. The dominant theme is stable, cost-plus-funded environmental and administrative services, led by a $371.6 million DOE Hanford cleanup award to Central Plateau Cleanup Company (PAE-Parsons) and a $321.3 million DHS records support contract to Serco Services Inc. The highest-conviction signal is a bullish $173.3 million NIH clinical research contract to Technical Resources International, offering long-term, low-risk revenue through 2026. However, three of four contracts are either expired or near completion, limiting near-term revenue visibility. Key risk: the Serco and Millennium Engineering contracts are fully completed with no current financial impact, inflating the aggregate value relative to active revenue streams.

4 total filings
· daily

DOE Energy Grants — July 31, 2026

This digest covers a single, large civilian contract from the Department of Energy (DOE), a $371.6 million cost-plus award fee delivery order awarded to Central Plateau Cleanup Company, LLC (a PAE-Parsons joint venture) for remediation at the Hanford site. With zero defense-related awards, the signal is purely civilian and neutral, reflecting stable but non-transformational federal environmental spending. The highest-conviction signal is the contract's short 8-month performance period and cost-plus structure, which limits margin upside and revenue visibility despite the headline value. A key risk is that only $125.4 million has been outlaid against the obligation, suggesting potential funding flow delays or execution headwinds.

1 total filings
· daily

General Federal Contracts — July 31, 2026

Across four general federal contracts valued at $1.07 billion, all are civilian (0% defense), signaling a concentrated civilian agency theme. The Department of Energy’s $371.6 million remediation contract at Hanford (Central Plateau Cleanup Company, a PAE-Parsons subsidiary) commands the highest materiality, though its short 8-month performance period and low outlay ($125M) limit near-term visibility. The only bullish signal with high conviction is Technical Resources International, Inc.’s $173.3 million clinical research support contract with NIH, offering a stable, nearly decade-long revenue stream for a small, woman-owned contractor. Key risk: the Serco Services Inc. $321.3 million DHS contract is expired and has no current financial impact, but its past scale highlights Serco’s enduring administrative service footprint. Investors should watch for option exercises on the DOE contract and NIH re-competes for Technical Resources.

4 total filings
· daily

All NASA Contracts — July 31, 2026

The sole NASA contract in this period, a $202.6 million cost-plus-fixed-fee award to MILLENNIUM ENGINEERING AND INTEGRATION SERVICES, LLC, is a legacy contract completed in 2021, offering no current revenue visibility. The aggregate is entirely civilian, with zero defense exposure, and the neutral signal strength (4/10) reflects the contract's age and lack of ongoing materiality. The highest-conviction signal is the absence of new awards, indicating a potential gap in NASA's engineering support spending at Ames Research Center. Key risk is the lack of a follow-on contract, which could signal a shift in NASA's procurement strategy or a loss of competitive position for the small business.

1 total filings
· daily

S&P 500 Technology Sector SEC Filings — July 31, 2026

The S&P 500 Technology sector shows a bifurcated landscape this period. Apple Inc. delivered a standout performance with 16% YoY revenue growth and a 27% surge in net income, driven by iPhone, Mac, and Services, while its balance sheet strengthened significantly with a 45.8% increase in shareholders' equity. However, insider activity signals caution: a top executive at Accenture sold $577K under a 10b5-1 plan, and Adobe's SVP & CAO sold shares, suggesting profit-taking or internal caution. Passive institutional ownership remains strong, with Vanguard confirming 7.63% and 5.52% stakes in Marvell Technology and Autodesk, respectively. Qualcomm's filing relates to the Modular Inc. acquisition, a non-operational event. Overall, the sector is characterized by strong operational performance at scale (Apple) but mixed signals from insider transactions, warranting a selective approach. The lack of forward-looking guidance or period-over-period comparisons in most filings limits trend analysis, but Apple's data provides a clear positive anchor.

6 high priority 3 medium 9 total filings
· daily

Nasdaq 100 Stocks SEC Filings — July 31, 2026

The 14 filings from NASDAQ-100 constituents reveal a mixed picture of strong operational performance offset by rising capital intensity and insider caution. Amazon and Apple posted robust revenue growth of 19.6% and 16% YoY respectively, with Apple's net income surging 27% YoY, but Amazon's free cash flow remains negative due to $173B in trailing capex. Linde showed solid 9% sales growth but experienced margin compression across all segments (50-120 bps), while raising full-year EPS guidance to $17.70-$17.90. Insider activity is predominantly negative, with three separate insider sales at ADP, Adobe, and Intuitive Surgical, though two Intuit directors exercised options at $529.97, signaling confidence. The most critical development is Amazon's $90/share acquisition of Globalstar, structured as a tax-free reorganization with regulatory and operational milestones pending. A major cybersecurity incident at Amgen involving exfiltration of proprietary data and patient PHI represents a significant risk. Capital allocation trends show increased share repurchases and dividends at Linde, while Apple's shareholders' equity surged 45.8% as retained earnings turned positive. Overall, the portfolio shows strong top-line growth but faces headwinds from cost inflation, heavy investment cycles, and selective insider selling.

11 high priority 3 medium 14 total filings
· daily

US Activist Hedge Fund Institutional SEC 13D 13G — July 31, 2026

The July 31, 2026 filings reveal a significant divergence in institutional and activist activity. Vanguard Capital Management made a broad, passive push across 25+ companies, crossing the 5% threshold in 16 names (e.g., Compass, Anavex, Conagra) while reducing or exiting positions in 8 others (e.g., Associated Banc-Corp, Chatham Lodging), signaling a portfolio rotation. Activist activity is concentrated in Scully Royalty Ltd., where the Kellogg group (35.5% stake) and Neil Subin (13.0%) are engaged in a proxy fight and litigation over the 2025 AGM, creating a high-stakes control battle. Capital World Investors maintained its 34.9% stake in Diebold Nixdorf, while RA Capital executed a strategic exchange of shares for pre-funded warrants at Inhibikase Therapeutics to cap ownership at 9.99%. Insider selling is notable at Sanara MedTech (complete exit by Tall Pines Capital) and Diana Shipping (stake fell below 5%). The overall theme is one of passive rebalancing by Vanguard, mixed with targeted activist pressure and strategic positioning by specialized funds.

9 high priority 41 medium 50 total filings
· daily

S&P 500 Financials Sector SEC Filings — July 31, 2026

The S&P 500 Financials sector is experiencing a notable bifurcation between strong earnings growth at scale and underlying capital flow challenges. Bank of America and Truist reported double-digit net income growth (26.5% and 25.2% YoY, respectively), driven by robust non-interest income and improved efficiency ratios. However, asset managers like T. Rowe Price confront a significant divergence between record AUM ($1.9T, up 12.9% YoY) and persistent net client outflows ($6.5B in Q2 2026), signaling potential revenue headwinds from fee compression and asset mix shifts. Insider trading activity provides a powerful contrarian signal: a Vice Chair at Visa executed a large $13.6M stock sale following option exercises, while an executive at Marsh & McLennan made a smaller but notable sale. Capital deployment remains aggressive, with T. Rowe Price returning $441M to shareholders and Truist executing substantial buybacks that reduced equity. The Interactive Brokers' shelf takedowns suggest ongoing capital market activity, while weak insider filings (Coinbase) create noise. The key takeaway is that top-line growth is masking idiosyncratic risks in asset management and potential insider sentiment divergence in payments.

5 high priority 4 medium 9 total filings
· daily

S&P 500 Energy Sector SEC Filings — July 31, 2026

The S&P 500 Energy sector is experiencing a powerful earnings boom driven by surging commodity prices, with Brent crude averaging $104/BBL in Q2 2026 versus $68/BBL a year ago. Chevron and ExxonMobil both reported massive year-over-year earnings increases, with Chevron's net income surging from $2.5B to $12.1B and ExxonMobil posting a 247% sequential GAAP earnings jump. However, the picture is nuanced: U.S. natural gas realizations have collapsed to $0.91/MCF from $1.75/MCF, and downstream demand is weakening, with refined product sales falling 13% internationally and 4% in the U.S. Vanguard's passive 13G filings for Devon Energy, SLB, and Valero signal continued institutional confidence in the sector's long-term value, while a small insider purchase at Texas Pacific Land Corp suggests management alignment. The key portfolio-level theme is a tale of two markets: upstream producers are thriving on high oil prices, but downstream and natural gas segments face headwinds from demand destruction and supply disruptions.

1 high priority 5 medium 6 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — July 31, 2026

The S&P 500 Consumer Staples sector is showing a clear bifurcation in Q2 2026: companies with strong brand portfolios and e-commerce capabilities (Church & Dwight, Colgate-Palmolive) are delivering organic growth and margin expansion, while those facing portfolio restructuring or regional weakness are seeing profit compression. Church & Dwight stands out with organic sales growth of 5.8% and a 22.7% surge in global e-commerce, now representing over a quarter of sales, but reported net sales were flat due to strategic portfolio actions. Colgate-Palmolive reported a 4.9% net sales increase with a 140 bps gross margin expansion to 61.5%, yet GAAP EPS fell 5% due to restructuring costs, and North America sales declined 3.0%. Both companies are increasing shareholder returns via dividends and buybacks, signaling management confidence, but rising long-term debt at Colgate ($7.8B vs $6.9B) and a sharp cash decline at Church & Dwight ($254.8M from $409.0M) due to a $300M acquisition warrant caution. The passive 5%+ stakes disclosed by Vanguard in Dollar General and Estee Lauder suggest institutional accumulation in undervalued staples names, but provide no operational signals. The overarching theme is that operational excellence and digital transformation are driving outperformance, while legacy portfolio issues and regional headwinds are creating divergence within the sector.

2 high priority 4 medium 6 total filings
· daily

S&P 500 Industrials Sector SEC Filings — July 31, 2026

The six filings reveal a bifurcated industrial landscape: Eaton Corp's record top-line growth (21% YoY) and raised guidance signal robust demand in electrical markets, but this is overshadowed by a 16.4% GAAP net income decline, 80 bps YoY margin compression, and a massive debt-fueled acquisition spree ($11B in cash for acquisitions, debt up 111% to $18.5B). The Mobility segment's organic sales decline (-2% YoY) and eMobility's -13.7% drop highlight a weak spot, prompting the planned separation via Reverse Morris Trust. Insider selling at ADP ($280K by a Corp VP under a 10b5-1 plan) is a minor negative signal. Meanwhile, Vanguard's 13G filings for Honeywell Aerospace (7.54% stake) and FedEx Freight (5.5% stake) confirm passive institutional accumulation in two newly spun-off or pure-play industrial names, suggesting a sector rotation toward simpler, high-quality assets. The overarching theme is a 'growth vs. quality' trade-off: Eaton is buying growth at the expense of balance sheet strength and margins, while Vanguard's passive bets favor clean, capital-light structures.

3 high priority 3 medium 6 total filings
· daily

US Material Events SEC 8-K Filings — July 31, 2026

The July 31, 2026, filing batch reveals a market sharply bifurcated between strategic transformation and financial distress. The most significant theme is a wave of high-impact M&A and divestitures, including Deluxe Corp's transformative acquisition of Celero Commerce (expected to add $70B in annual volume and be accretive to EPS), Vireo Growth's acquisition of Planet 13 Holdings, and Dragonfly Energy's bolt-on purchase of Dakota Lithium. Concurrently, several companies are executing capital raises under duress, such as Co-Diagnostics' dilutive warrant inducement and Beyond Air's $30.1M private placement, signaling cash burn in the biotech and small-cap sectors. Leadership transitions are widespread, with notable CFO departures at Warner Music, Tredegar, and Arrive AI, while insider loan activity at BTCS Labs and a failed acquisition at Marquie Group highlight micro-cap fragility. The data shows a clear pattern: larger, cash-flow-positive companies are using M&A to accelerate growth, while smaller, cash-constrained firms are resorting to dilutive financing and restructuring to survive.

50 high priority 50 total filings
· daily

Insider Trading Pulse — July 31, 2026

The July 31, 2026 insider trading digest reveals a pronounced bearish tilt, with 15 open-market sales by C-suite executives and directors totaling over $6.8 million, while only two small open-market purchases were recorded. Key period-over-period trends from the enriched data show a pattern of insider profit-taking following stock option exercises, particularly at ACME UNITED CORP, ECOLAB, and ENTERGY, where executives exercised low-cost options and immediately sold shares at higher market prices. The most critical development is the concentrated selling at WORLD KINECT CORP, where two directors sold $1.74 million in stock on the same day, signaling potential concern. Sector themes include a notable cluster of CFO selling (ECOLAB, HASBRO, PRECIGEN) and a wave of director option awards at ACME UNITED CORP, suggesting a compensation refresh. The data also reveals significant insider pledges and gifts, including a massive 1.5 million share gift by EchoStar's CEO, which may have estate planning or tax implications. Overall, the digest points to elevated insider selling relative to buying, warranting caution in names with multiple insider disposals.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — July 31, 2026

The seven filings from Dow 30 constituents reveal a stark divergence between tech-driven growth and traditional energy volatility. Apple and Amazon posted exceptional revenue and earnings growth, with Apple's net income surging 27% YoY and Amazon's EPS jumping to $5.75 from $1.68, though Amazon's heavy capex ($173B TTM) keeps free cash flow negative. Chevron's earnings skyrocketed to $12.1B from $2.5B on higher oil prices, but its natural gas realizations halved and downstream volumes declined, signaling mixed health. The Amazon-Globalstar S-4 filing introduces a major strategic pivot into satellite communications, with a delayed launch timeline and complex merger terms. A material cybersecurity incident at Amgen and a large insider sale at Visa add risk signals. Vanguard's passive 7.54% stake in Honeywell Aerospace confirms institutional interest in the aerospace spin-off. Period-over-period trends show robust revenue growth across tech (16-20% YoY) but capital allocation diverging sharply—Apple returning cash via buybacks, Amazon investing aggressively, and Chevron benefiting from commodity tailwinds.

5 high priority 2 medium 7 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 31, 2026

On July 31, 2026, a concentrated wave of eight Nasdaq-listed micro-cap companies filed 8-Ks revealing they have fallen below the $1.00 minimum bid price, triggering deficiency notices and potential delisting. This cluster represents a significant distress signal for the small-cap biotech and healthcare sector, with all eight companies facing 180-day cure periods expiring between January 25 and January 27, 2027. Notably, bioAffinity Technologies faces an accelerated risk as it is ineligible for a standard cure period due to a prior reverse stock split, and must appeal by August 6, 2026, to avoid immediate delisting. The filings show no insider buying or positive forward guidance to offset the distress, and several companies (DocGo, PDS Biotechnology, Context Therapeutics) are explicitly considering reverse stock splits—a historically value-destructive measure. The uniformity of the distress across these filings suggests a broader market rotation away from speculative micro-cap equities, with no positive period-over-period trends or capital allocation signals to provide a counter-narrative. The most critical development is the impending August 6 appeal deadline for bioAffinity, which will serve as a bellwether for the group's ability to navigate Nasdaq's listing standards.

8 high priority 8 total filings